<p><strong>CUPERTINO &#8212; </strong><u>MindRhythm</u>, a medical technology company focused on preventing neurological injury in stroke, has raised $5 Million in an oversubscribed round of seed funding.</p>
<p>A diverse group of investors participated in the round, with a mix of family office, venture capital, and individuals dedicated to the company&#8217;s mission: Principal investors include Pierre and David Lamond; Corey Goodman, PhD, Managing Partner of venBio and Board Chairman for MindRhythm; <a href="https://pr.report/xmZnuVhJ"><u>DCVC</u></a>; Aestus Capital; <u>Perseverance Capital Management</u>; Blue Fog Capital; Franklin Berger, Managing Director at FMB Research and Kyle York, CEO and managing partner of <u>York IE</u>. Early funding was provided by Laman Ventures, the venture fund of Lou Lavigne, former EVP and CFO of Genentech, and his wife Nancy Rothman. The company was incorporated in 2019 by John Keane, President and CEO; Wade Smith, MD, PhD, Professor of Neurology at the <u>UCSF Weill Institute for Neurosciences</u>, and President of <u>The Neurocritical Care Society</u>; and Paul Lovoi, PhD, CTO and product inventor.</p>
<p>Stroke is the fifth leading <u>cause of death</u> and a leading cause of permanent disability in the United States. MindRhythm&#8217;s Harmony device is a novel, non-invasive, diagnostic medical device that is designed to be used in an EMS setting to rapidly identify potentially lethal large vessel occlusion (LVO) strokes. These patients will benefit from rapid transport to a Comprehensive Stroke Center (CSC) that has the capabilities necessary to perform the treatment that will optimize outcomes. Small Vessel Occlusion (SVO) patients will be rapidly transported to a Primary Stroke Center (PSC), thus expediting care for all stroke patients.</p>
<p>This oversubscribed seed round underscores the importance of stroke triage and the need to improve outcomes for all stroke patients. MindRhythm&#8217;s finely-tuned, proprietary technology, developed in conjunction with UCSF, accurately stratifies stroke patients, communicates patient data, and provides remote location status to hospital teams prior to arrival thus optimizing patient treatment and outcomes. The funding from this round will allow MindRhythm to complete the clinical trial, demonstrating effectiveness of the device in the EMS environment.</p>
<p>&#8220;With stroke as one of the top causes of death and disability in the United States, MindRhythm intends to provide EMS professionals the ability to more easily identify and triage strokes, ensuring patients arrive at a hospital that can treat them in the quickest time possible,&#8221; said John Keane, President and CEO, MindRhythm. &#8220;This round of funding will allow us to further our mission of optimizing stroke triage prehospital, speeding time to treatment and reducing morbidity and mortality in emergent stroke.&#8221;</p>
<p>&#8220;I am extremely proud to be backing MindRhythm to help solve this well-known problem in stroke,&#8221; said Goodman. &#8220;The MindRhythm team is made up of some of the best and brightest in commercialization, medicine and science, and their unique approach, similar to the STEMI protocol with heart attacks, has the opportunity to make a major impact in medical technology.&#8221;</p>

SAN FRANCISCO -- Wearlinq, a provider of wearable health monitoring and diagnosis solutions, has announced…
SOUTH SAN FRANCISCO -- Link Cell Therapies, an oncology cell therapy company, announced its official…
SAN JOSE — Roku invites viewers to pack their bags for “Broad Trip,” a road…
SAN FRANCISCO — Data and AI company Databricks has snagged a massive $4 billion-plus Series…
For 25 years, the NVIDIA Graduate Fellowship Program has supported graduate students doing outstanding work…
SAN FRANCISCO -- Fal, a real-time generative-media platform powering the next decade of AI-driven content,…